Cost-Benefit and Cost-Effectiveness Analysis of Drug Abuse Treatment Services

William S. Cartwright
Additional contact information
William S. Cartwright: National Institutes of Health

Evaluation Review, 1998, vol. 22, issue 5, 609-636

Abstract: The foundations of cost-benefit analysis and cost-effectiveness analysis (CB/CEA) for drug abuse treatment are developect An economic model of addict choice and drug markets is presented. This model is synthesized with the current "cost of illness" methods used to measure the burden of the disease to society. The problem of doing cost-effectiveness studies in the presence of large nonhealth benefits is examined, and guidance is offered to clinical studies with a cost-effectiveness component or to stand-alone cost-effectiveness studies. References and an extensive bibliography on drug abuse treatment-related CB/CEA studies are appended.

Date: 1998
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0193841X9802200503 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:evarev:v:22:y:1998:i:5:p:609-636

DOI: 10.1177/0193841X9802200503

Access Statistics for this article

More articles in Evaluation Review
Bibliographic data for series maintained by SAGE Publications ().